Open to Innovation: A Conversation with Johnson & Johnson Pharma R&D Chief Paul Stoffels
Executive Summary
Johnson & Johnson believes its future success is directly dependent on its ability to access best-in-class science via more flexible, less risky partnerships. The health care giant's global head of pharmaceutical R&D, Paul Stoffels, explains in greater detail J&J's open innovation model.
You may also be interested in...
Best of the Blog February 2010
Best of the blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In February, Windhover's editorial staff posted 26 articles to the site, covering biopharma R&D, business development, regulatory, and commercial news.
Best of the Blog February 2010
Best of the blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In February, Windhover's editorial staff posted 26 articles to the site, covering biopharma R&D, business development, regulatory, and commercial news.
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. Earlier stage biotechs are trying to turn their platforms into research revenue as they look to non-profit, government, and private funding sources to advance their preclinical therapeutic programs. Whatever the model, worries abound that the financial woes of the next couple of years could blunt hard-earned momentum.